Skip to main content Skip to footer
Novakand Pharma
  • Home
  • About us
    • Our Business
    • Strategy and business model
    • Management
    • Board of Directors
    • Contact us
  • Pipeline
    • Our Science
    • Pipeline overview
    • Projects
      • Rugocrixan
      • Fosrugocrixan
    • Business Development
    • IP
    • Publications
  • Therapeutic areas
    • Myocardial infarction
    • Ovarian cancer
  • Investors
    • Presentations
    • Press Releases
    • Financial Reports
    • Financial Calendar
    • Events
    • The Share
    • Sustainability
    • Corporate Governance
      • Articles of Association
      • Annual General Meeting
      • Board Committee
      • Board
      • CEO and Management
      • Auditors
      • Certified Adviser
  • Home
  • About us
    • Our Business
    • Strategy and business model
    • Management
    • Board of Directors
    • Contact us
  • Pipeline
    • Our Science
    • Pipeline overview
    • Projects
      • Rugocrixan
      • Fosrugocrixan
    • Business Development
    • IP
    • Publications
  • Therapeutic areas
    • Myocardial infarction
    • Ovarian cancer
  • Investors
    • Presentations
    • Press Releases
    • Financial Reports
    • Financial Calendar
    • Events
    • The Share
    • Sustainability
    • Corporate Governance
      • Articles of Association
      • Annual General Meeting
      • Board Committee
      • Board
      • CEO and Management
      • Auditors
      • Certified Adviser
  • Svenska
Start>News>Regulatory>MAR

MAR

  • Interim Report Second Quarter April 1 – June 30 2023 Kancera AB (publ.), org.no. 556806-8851

    18 August 2023

  • Kancera appoints Peter Selin as new Chief Executive Officer

    26 May 2023

  • Interim report for first quarter 2021, 1 January – 31 March 2021

    21 May 2021

  • Interim report for the second quarter 2020. January 1st – June 30th, 2020

    21 August 2020

  • Interim report for the second quarter 2019, 1 January – 30 June 2019

    23 August 2019

  • INTERIM REPORT FOR THE FIRST QUARTER 2019, 1 January – 31 March 2019

    24 May 2019

  • INTERIM REPORT FOR KANCERA  AB (publ) 1st January – 30th September 2018

    23 November 2018

  • Time plan for Kancera’s rights issue

    27 April 2018

  • YEAR END REPORT KANCERA  AB (publ) 1st January – 31st December 2017

    20 February 2018

  • Kancera performs the second partial payment for the Fractalkine project

    21 November 2017

+46 (0)8 5012 60 80Nanna Svarts väg 4, 171 65 Solna, Sweden

Content

  • Home
  • About us
  • Pipeline
  • Therapeutic areas
  • Investors

Shortcuts

  • Press Releases
  • Financial Reports
  • Financial Calendar
  • Website Policy

Copyright © 2025 Novakand AB. All Rights Reserved. Design by Clavis Communications